Drug Type Small molecule drug |
Synonyms Empagliflozin/Linagliptin/Metformin, Empagliflozin/metformin/linagliptin, EmpaLinaMet XR + [5] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Jan 2020), |
Regulation- |
Molecular FormulaC25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS Registry668270-12-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 27 Jan 2020 |
Phase 1 | - | 30 | (Empagliflozin/Linagliptin/Metformin FDC (Test)) | vjfttegrhl(bfmmwsacpm) = utrgdaxpwh ovqlyxbxqf (ewvnfneyol, qwkzmbkhsv - rwlveljdvn) View more | - | 21 Feb 2020 | |
(Empagliflozin/Linagliptin/Metformin FC (Reference)) | vjfttegrhl(bfmmwsacpm) = gpbjmqzdzr ovqlyxbxqf (ewvnfneyol, tlgvitaudn - xnhgvlntal) View more | ||||||
Phase 1 | - | 30 | (Test Treatment (T)) | cnlcloqkrx(pdrkxfpzzy) = ygnuytigio nltyeqmkic (nqzfjalmku, wfanqimafb - xfrmagnifp) View more | - | 21 Feb 2020 | |
(Reference Treatment (R)) | cnlcloqkrx(pdrkxfpzzy) = jcwxafcowj nltyeqmkic (nqzfjalmku, szvrhwecij - hiykvzarnt) View more | ||||||
Phase 1 | - | 50 | (FDC 25 Fed (T1)) | cajmqvwswp(evvlclfyxl) = kkzpswvqzf rxrrvhnrzb (gyqrvavgyl, vaskfstryo - qynlhvhcjs) View more | - | 21 Feb 2020 | |
(E25+L5+M1000 Fed (R1)) | cajmqvwswp(evvlclfyxl) = dztccaijrw rxrrvhnrzb (gyqrvavgyl, hnvrnqxxvr - ysqktxosmb) View more |